Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Riboflavin Placebo Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 17, 2026, 1:34 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Evaluation of Progression of Myopia in Children Treated With Vitamin B2 and Outdoor Sunlight Exposure

NCT03552016
View directory record Official record
Conditions
Axial Myopia, Refractive Errors
Interventions
Oral Riboflavin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
6 Years to 12 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Test Article A, Test Article B, Placebo, KXL medical device system
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 17, 2026, 1:34 PM EDT
Recruiting Phase 2 Interventional

Magnesium and Riboflavin Treatment for Post-Concussion Headache

NCT06260072
View directory record Official record
Conditions
Concussion, Intermediate
Interventions
magnesium and riboflavin supplement
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Quetiapine on Marijuana Withdrawal and Relapse

NCT00743366
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Marijuana, Quetiapine, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 17, 2026, 1:34 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Trial of Nepicastat for Cocaine Dependence

NCT01704196
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Nepicastat, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 17, 2026, 1:34 PM EDT
Completed No phase listed Observational

Vitamins, Breastmilk HIV Shedding, and Child Health

NCT00197756
View directory record Official record
Conditions
Maternal and Child Health Outcomes
Interventions
Vitamin A alone, Multivitamins excluding vitamin A, multivitamins including vitamin A, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older · Female only
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01344187
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Irvine, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes

NCT05907850
View directory record Official record
Conditions
Muscle Soreness
Interventions
Riboflavin, Placebo
Drug
Lead sponsor
Steven Moore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 17, 2026, 1:34 PM EDT
Terminated Phase 3 Interventional Results available

Study of Rifampicin in Multiple System Atrophy

NCT01287221
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Rifampicin, placebo
Drug
Lead sponsor
Phillip Low
Other
Eligibility
30 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Ramelteon in the Prevention of Post-operative Delirium

NCT02324153
View directory record Official record
Conditions
Delirium, Delirium, Dementia, Amnestic, Cognitive Disorders, Delayed Emergence From Anesthesia, Cognitive Disorders
Interventions
Ramelteon, Microcrystalline Cellulose, Riboflavin 100 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 4 Interventional

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

NCT03012529
View directory record Official record
Conditions
Osteomyelitis, Diabetes, Amputation
Interventions
Rifampin, Riboflavin Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Trial of Vitamins in HIV Progression and Transmission

NCT00197743
View directory record Official record
Conditions
HIV Infections, Disease Transmission, Vertical
Interventions
Vitamin A + Beta Carotene, Multivitamins, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older · Female only
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Sep 17, 2026, 1:34 PM EDT
Withdrawn Not applicable Interventional

Monitoring the Effects of Probiotic Supplementation in Immunocompromised Kidney Transplanted Subjects

NCT05102461
View directory record Official record
Conditions
Diarrhea Caused by Drug, Dysbiosis
Interventions
Florajen Digestion Supplementation, Placebo Supplementation
Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

NCT06100952
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment
Combination Product
Lead sponsor
Epion Therapeutics
Industry
Eligibility
8 Years to 45 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention

NCT02896712
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Acceptance and Commitment Therapy (ACT), Drug Counseling (DC), Contingency Management (CM), Placebo, Modafinil
Behavioral · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 17, 2026, 1:34 PM EDT
Terminated Phase 3 Interventional

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

NCT04616924
View directory record Official record
Conditions
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
Interventions
RHB-204, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
25
States / cities
Glendale, California • Palm Springs, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals

NCT00218062
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
D-Amphetamine 30mg, D-Amphetamine 60mg, Modafinil 200mg, Modafinil 400mg, Therapy, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Varenicline: Testing Individual Differences

NCT01228175
View directory record Official record
Conditions
Smoking Addiction
Interventions
Placebo, Varenicline
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 55 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Baclofen on Marijuana Withdrawal and Relapse

NCT00373295
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Baclofen, Marijuana, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 17, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Tolcapone for Cognition in Schizophrenia

NCT00044083
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Tolcapone
Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

NCT00770146
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Mipomersen sodium, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
62
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 17, 2026, 1:34 PM EDT
Completed Phase 2Phase 3 Interventional

Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia

NCT00567671
View directory record Official record
Conditions
Progressive Keratoconus, Corneal Ectasia
Interventions
Corneal collagen, Sham comparator
Procedure
Lead sponsor
Emory University
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2010 · Synced Sep 17, 2026, 1:34 PM EDT